Veronica Hall

Oversaw pipeline program development for all 4 business units: Vaccines and Anti-ineffective, Antibody Therapeutics, Devices, and Commercial Manufacturing. Continuation of Director responsibilities - secured yearly R&D revenue >$75M; annually built project budgets up to $100M and ensured accountability for over 20 projects annually with >$250K budget per project; maintain >$1M budget for operational expenses; led and developed up to 9 diverse, advanced degree individuals to collaborative, cohesive, high performing business unit team. • Launched and secured company’s position in new field by securing $23M in R&D from revenue partner for high-risk project in critical therapeutic space. • Grew enterprise wide opportunity pipeline, resulting in 25% increase year over year in qualified opportunities and >$75M in annual R&D partnership revenue. • Diversified R&D pipeline by identifying 8 vaccines, therapeutics, or drug/device combination products. • Secured largest award of $1.6B from strategic alliance that advanced company’s first cradle to grave vaccine to Phase 3 clinical studies. • Expanded the medical device portfolio and secured $63M in revenue by creating strategic alliances.

Oversaw vaccine pipeline development; secured yearly R&D revenue above $75M; annually built project budgets up to $100M and ensured accountability for over 10 projects annually for up to $250K budget per project; maintain >$1M for operational expenses; led and developed up to 2 diverse, advanced degree individuals to collaborative, cohesive, high performing business unit team. • Spearheaded corporate response to 2014-2015 Ebola outbreak, resulting in ~$30M from revenue partners for product development and delivery of critical medical countermeasures to the field for implementation. • Diversified corporate portfolio into drug device combination therapeutics by identifying initial autoinjector medical device that led to formation of the medical device business unit. • Supported life-cycle management of vaccine franchise that secured $23M to develop next generation vaccine and led cross-functional team in developing product development plan. • Expanded corporate presence allowing for diversification of the pipeline by creating key customer relationships. • Enhanced corporate capabilities through development and cultivation of strategic alliances with 3 non-profit organizations.

Facilitated development of integrated product development plans for vaccines leading cross-functional teams; continued Manager responsibilities - led R&D non-dilutive funding efforts through traditional USG awards to support advance development of the R&D pipeline; managed a team of 2 professionals • Expanded corporate manufacturing capacity 30%, secured > $200M for facility renovations, identified key teaming partners, and led the cross-functional team in developing approach. • Initiated strategic alliance that enhanced corporate capability and led to 2 additional products in device pipeline and > $60M in R&D funding

Spearheaded European funding efforts for tuberculosis (TB) vaccine development; led R&D non-dilutive funding efforts through traditional USG awards to support advance development of the R&D pipeline; managed 1 professional. • Secured high profile meeting with CEO and the EU Directorate General of Research (similar to US Cabinet position) through EU relationship efforts. • Insured viability of next generation vaccine by influencing senior management to pursue opportunity leading to >$20M award for advance development.

Led proposal response efforts to secure non-dilutive funding for advancement of the R&D pipeline; interacted with the EU at both the parliamentary level and directorate general level. • Increased corporate international profile by presenting corporate capabilities and pipeline to EU parliamentary members and key posts in the Directorate Generals. • Secured >$200M in R&D awards leading proposal response efforts.

Created technical strategies for studying immunological effects in the tumor micro- environment. Mentored in the Experimental Therapeutic Laboratory under former CCR director Dr. Robert Wiltrout. Guided Post-baccalaureate students and research technician. • Increased engagement of the Post-Doctoral Fellows and Young Investigator Committee by serving as Vice-President and organizing a 3-day scientific conference for over 1400 young scientist and post-doctoral fellows. • Established critical partnerships with external collaborators to synergize capabilities leading to 6 peer-reviewed scientific publications.